Physician profile
Michael Daniel
NPI 1275896649
$13,271.61
in general payments reported to CMS, 2019-2025
45 companies · $2,450 in 2025
The $2,450 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,368 · 2020: $837 · 2021: $864 · 2022: $1,528 · 2023: $3,525 · 2024: $1,700 · 2025: $2,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,262 · Travel and Lodging: $1,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,261.58 |
| Travel and Lodging | $1,413.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,023.92 | 2019-2025 | General - Vascular Access, Watchman Flx, Avvigo Guidance System |
| Abbott Laboratories | $1,746.05 | 2019-2024 | Mitraclip, Merlin@Home, Advisor |
| Medtronic, INC. | $1,337.68 | 2021-2025 | Corevalve Evolut R, Na, Selectsecure |
| Shockwave Medical, INC | $1,182.00 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Philips North America LLC | $741.41 | 2019-2020 | |
| Edwards Lifesciences Corporation | $642.48 | 2019-2025 | Sapien 3 Ultra Resilia |
| Kestra Medical Technology Services, INC. | $354.33 | 2024-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $318.00 | 2020-2025 | Eliquis, Camzyos |
| Cardiovascular Systems INC. | $270.08 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $255.32 | 2021-2025 | Verquvo, Steglatro, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $252.77 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $231.26 | 2020-2024 | |
| Cvrx, INC. | $214.59 | 2022-2025 | Barostim Neo System |
| Pfizer INC. | $165.12 | 2021-2025 | |
| Abiomed | $162.00 | 2024 | Impella |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.